Phase
Condition
N/ATreatment
Blood Sample Collection
Tumor Tissue Collection
Tumor Imaging
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Has histologically- or cytologically-confirmed diagnosis of Stage IV squamous ornonsquamous NSCLC
Participants with nonsquamous NSCLC who are not eligible for an approved targetedtherapy
Is able to to provide archival tumor tissue sample collected either within 5 yearsor within the interval from completion of last treatment but before entering thescreening period or newly obtained core or excisional biopsy of a tumor lesion notpreviously irradiated obtained within 90 days of treatment initiation
Has not received prior systemic treatment for their metastatic NSCLC
Has adequate organ function within 10 days of initiation of study treatment
Male participants must agree to use contraception and should refrain from donatingsperm during the treatment period and:
Substudy 01A: for at least 120 days after the last dose of pembrolizumab and for atleast 180 days after the last dose of chemotherapy
Substudies 01B and 01C: for at least 120 days after study treatments
Substudy 01E: for at least 100 days after the last dose of MK-2870 or MK-7684A, andfor at least 90 days after the last dose of radiation therapy
Substudy 01G: for at least 90 days after the last dose of chemotherapy or 120 daysafter the last dose of HER3-DXd
Substudies 01H and 01I: for at least 120 days after the last dose of I-DXd or R-DXdand 95 days after the last dose of docetaxel
Female participants must not be pregnant or breastfeeding, and at least 1 of thefollowing conditions apply:
Not a woman of childbearing potential (WOCBP), OR
A WOCBP who agrees to use contraception during the treatment period and:
Substudy 01A: for at least 120 days after the last dose of pembrolizumab and for atleast 180 days after the last dose of chemotherapy.
Substudies 01B and 01C: for at least 120 days after study treatment
Substudy 01E: for at least 120 days after the last dose of pembrolizumab, 190 daysafter the last dose of MK-2870, 120 days after the last dose of MK-7684A, 120 daysafter the last dose of vibostolimab, 190 days after the last dose of chemotherapy,and 180 days after the last dose of radiation therapy
Substudy 01G: for at least 120 days after the last dose of pembrolizumab, 180 daysafter the last dose of chemotherapy, and 210 days after the last dose of HER3-DXd
Substudies 01H and 01I: for at least 210 days after the last dose of I-DXd or R-DXdand 35 days after the last dose of docetaxel
Substudies 01A, 01B, and 01C only:
Is able to complete all screening procedures within the 35-day screening window
Substudies 01A and 01B only:
Has not received prior systemic treatment for their metastatic NSCLC
Substudy 01B only:
Has a programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%
Substudy 01C only:
Has progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb)administered either as monotherapy, or in combination with other checkpointinhibitors or other therapies
Has progressive disease during/after platinum doublet chemotherapy
Substudy 01E only:
Participant has previously untreated and pathologically confirmed resectable StageII, IIIA, or IIIB (N2) NSCLC per American Joint Committee on Cancer 8th Edition
Tumors must be resectable in the judgment of a thoracic surgeon
Exclusion
Exclusion Criteria:
Has preexisting neuropathy that is moderate in intensity
Has received a live or live-attenuated vaccine within 30 days before the first doseof study treatment. Any licensed COVID-19 vaccine (including for Emergency Use) in aparticular country is allowed as long as they are messenger ribonucleic acid (mRNA)vaccines, adenoviral vaccines, or inactivated vaccines. Investigational vaccines (ie, those not licensed or approved for Emergency Use) are not allowed
Is currently participating in or has participated in a study of an investigationalagent or has used an investigational device within 4 weeks before the first dose ofstudy treatment
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form ofimmunosuppressive therapy within 7 days before the first dose of study treatment
Has an active autoimmune disease that has required systemic treatment in the past 2years
Has a history of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease
Has an active infection requiring systemic therapy
Has a known history of HIV infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has had an allogenic tissue/solid organ transplant
Substudies 01A, 01B, and 01C only:
Has a diagnosis of small cell lung cancer
Has a known additional malignancy that is progressing or has required activetreatment within the past 2 years
Has known active central nervous system (CNS) metastases and/or carcinomatousmeningitis
Has clinically significant cardiac disease, including unstable angina, acutemyocardial infarction within 6 months from Day 1 of study treatment administration,or New York Heart Association Class III or IV congestive heart failure
Has had major surgery <3 weeks before the first dose of study treatment
Is expected to require any other form of antineoplastic therapy while on study
Has received prior radiation therapy to the lung that is >30 Gray (Gy) within 6months of the first dose of study treatment
Has received any prior immunotherapy and was discontinued from that treatment due toa severe or worse immune-related adverse event (irAE)
Has had chemotherapy or biological cancer therapy within 4 weeks before the firstdose of study treatment or has not recovered to Common Terminology Criteria forAdverse Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeuticsadministered more than 4 weeks before the first dose of study treatment (includingparticipants who had previous immunomodulatory therapy with residual irAEs)
Previously had a severe hypersensitivity reaction to treatment with monoclonalantibodies (including pembrolizumab) and/or any of their excipients
Is pregnant or breastfeeding or expecting to conceive or father children within theprojected duration of the study, starting with the screening visit through 120 daysafter the last dose of study treatment
- Substudy 01A only:
Has symptomatic ascites or pleural effusion (if receiving pemetrexed)
Has a history or current evidence of a gastrointestinal (GI) condition (e.g.inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liverfunction or diseases that in the opinion of the investigator may significantly alterthe absorption or metabolism of oral medications
Is getting chemotherapy and has clinically active diverticulitis, intra-abdominalabscess, GI obstruction, or peritoneal carcinomatosis
Is unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than aspirin dose less than or equal to 1.3 gm/day for a 5-dayperiod (8-day period for long acting agents such as peroxicam), for participants whowill receive pemetrexed
Is unable or unwilling to take folic acid or vitamin B12 supplementation, forparticipants who will receive pemetrexed
Has a known sensitivity to any component of carboplatin, paclitaxel, pemetrexed orany of their excipients
Substudies 01A and 01B only:
Has received prior systemic cytotoxic chemotherapy or other targeted or biologicalantineoplastic therapy for metastatic disease
Has received prior therapy with an anti-programmed cell death-1 (PD-1),anti-programmed cell death-ligand 1 (PD-L1), or anti-PD-L2 agent or prior therapytargeting other immunoregulatory receptors or mechanisms
Substudy 01C only:
Has received prior therapy targeting other immuno-regulatory receptors ormechanisms, not including anti-PD-(L)1 agents
Has participated in Substudies 01A or 01B
Substudy 01E only:
Has one of the following tumor locations/types:
NSCLC involving the superior sulcus
Large-cell neuro-endocrine cancer
Mixed tumors containing small cell and non-small cell elements
Sarcomatoid tumor
Documentation by local test report indicating presence of ALK generearrangements (ALK status not required and unknown or undetermined ALK statusare acceptable)
Has a known severe hypersensitivity (≥ Grade 3) to any of the investigational agentsand/or any of their excipients, the study chemotherapy agents and/or to any of theirexcipients, pembrolizumab and/or any of its excipients, and/or to another biologictherapy
History of documented severe dry eye syndrome, severe Meibomian gland disease and/orblepharitis, or corneal disease that prevents/delays corneal healing.
Has active inflammatory bowel disease requiring immunosuppressive medication orprevious history of inflammatory bowel disease
Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or withan agent directed to another stimulatory or coinhibitory T-cell receptor
Received prior radiotherapy within 2 weeks of start of study intervention, orradiation related toxicities, requiring corticosteroids
Has a known additional malignancy that is progressing or has required activetreatment within the past 5 years
Has not adequately recovered from major surgery or has ongoing surgicalcomplications
Substudy 01G only:
Has a known severe hypersensitivity (≥ Grade 3) to any of the investigational agentsand/or any of their excipients
Has active inflammatory bowel disease requiring immunosuppressive medication orprevious history of inflammatory bowel disease
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or withan agent directed to another stimulatory or coinhibitory T-cell receptor
Has a known additional malignancy that is progressing or has required activetreatment within the past 3 years
Study Design
Study Description
Connect with a study center
Petz Aladar Megyei Oktato Korhaz ( Site 0062)
Gyor, Gyor-Moson-Sopron 9024
HungaryActive - Recruiting
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0061)
Szolnok, Jasz-Nagykun-Szolnok 5000
HungaryActive - Recruiting
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)
Szolnok, Jasz-Nagykun-Szolnok 5004
HungaryActive - Recruiting
Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)
Budapest, 1121
HungaryActive - Recruiting
Soroka Medical Center ( Site 0072)
Beer-Sheva, 8457108
IsraelCompleted
Rambam Health Care Campus-Oncology ( Site 0076)
Haifa, 3109601
IsraelActive - Recruiting
Shaare Zedek Medical Center ( Site 0075)
Jerusalem, 9103102
IsraelActive - Recruiting
Meir Medical Center ( Site 0071)
Kfar-Saba, 4428132
IsraelActive - Recruiting
Rabin Medical Center ( Site 0074)
Petah Tikva, 4941492
IsraelActive - Recruiting
Chaim Sheba Medical Center ( Site 0070)
Ramat Gan, 5262000
IsraelActive - Recruiting
Sourasky Medical Center ( Site 0077)
Tel Aviv, 64239
IsraelSite Not Available
Sourasky Medical Center ( Site 0077)
Tel-Aviv, 6423906
IsraelActive - Recruiting
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Firenze 50134
ItalyActive - Recruiting
IRCCS Ospedale San Raffaele ( Site 0171)
Milano, 20132
ItalyActive - Recruiting
Policlinico Gemelli di Roma ( Site 0174)
Roma, 00168
ItalyActive - Recruiting
Seoul National University Bundang Hospital ( Site 0081)
Seongnam-si, Kyonggi-do 13620
Korea, Republic ofActive - Recruiting
Samsung Medical Center ( Site 0082)
Seoul, 06351
Korea, Republic ofActive - Recruiting
Severance Hospital ( Site 0080)
Seoul, 03722
Korea, Republic ofActive - Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warszawa, Mazowieckie 02-781
PolandActive - Recruiting
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Pomorskie 80-952
PolandActive - Recruiting
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdańsk, Pomorskie 80-952
PolandSite Not Available
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
Koszalin, Zachodniopomorskie 75-581
PolandSite Not Available
ICO L Hospitalet ( Site 0090)
Hospitalet de Llobregat, Barcelona 08907
SpainActive - Recruiting
Hospital Universitario Quiron Madrid ( Site 0091)
Pozuelo de Alarcon, Madrid 28223
SpainSite Not Available
Hospital Universitario Quiron Madrid ( Site 0091)
Madrid, 28223
SpainActive - Recruiting
Banner MD Anderson Cancer Center ( Site 0001)
Gilbert, Arizona 85234
United StatesActive - Recruiting
City of Hope ( Site 0014)
Duarte, California 91010
United StatesCompleted
UCSF Medical Center at Mission Bay ( Site 0007)
San Francisco, California 94158
United StatesCompleted
Georgetown University ( Site 0036)
Washington, District of Columbia 20007
United StatesActive - Recruiting
University of Kentucky Markey Cancer Center ( Site 0019)
Lexington, Kentucky 40536-0293
United StatesActive - Recruiting
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, Maryland 21237
United StatesActive - Recruiting
Dana Farber Cancer Institute ( Site 0002)
Boston, Massachusetts 02215
United StatesActive - Recruiting
Massachusetts General Hospital ( Site 0003)
Boston, Massachusetts 02114
United StatesActive - Recruiting
Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)
Omaha, Nebraska 68130
United StatesActive - Recruiting
Dartmouth Hitchcock Medical Center ( Site 0016)
Lebanon, New Hampshire 03766
United StatesActive - Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)
Hackensack, New Jersey 07601
United StatesCompleted
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034)
New York, New York 10016
United StatesActive - Recruiting
Sanford Fargo Medical Center ( Site 0039)
Fargo, North Dakota 58102
United StatesActive - Recruiting
Cleveland Clinic ( Site 0006)
Cleveland, Ohio 44195
United StatesActive - Recruiting
Cleveland Clinic Main ( Site 0006)
Cleveland, Ohio 44195
United StatesActive - Recruiting
Ohio State University Comprehensive Cancer Center ( Site 0015)
Columbus, Ohio 43210
United StatesActive - Recruiting
Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
Philadelphia, Pennsylvania 19104
United StatesActive - Recruiting
Sanford Cancer Center ( Site 0038)
Sioux Falls, South Dakota 57104
United StatesActive - Recruiting
The University of Texas MD Anderson Cancer Center ( Site 0009)
Houston, Texas 77030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.